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Abnormally elevated levels of serum cholesterol have
been demonstrated to contribute to atherosclerosis and
coronary artery disease. Statins, inhibitors of 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase, are efficient and widely used drugs in the
treatment of lipid disorders, especially hypercholes-
terolemia. In addition to their cholesterol-lowering
effects, statins are reported to inhibit tumour cell
growth 1,2. Statins are also known to synergistically
enhance the effects of chemotherapy 3,4 and to over-
come chemoresistance 5. Accordingly, statins prolong
the survival of patients with hepatocellular carci-
noma 4, and they reduce the risk of colorectal can-
cer 6 and breast cancer 7.
Statins induce apoptosis and reduce cell invasive-
ness in various cell lines, including malignant
glioma 8, neuroblastoma 9, myeloid leukemia 10, and
breast carcinoma 11. Cancer cells overexpress HMG-CoA
reductase 12. The chemopreventive activity of statins
against cancer is suggested to depend on inhibition
of HMG-CoA reductase in cholesterol synthesis and,
thereby, cell growth 13. The Ras protein is important
in the regulation of cell differentiation and prolifera-
tion. Statins are reported to inhibit the activation of
ras 14. The products of the mevalonate pathway are
necessary for diverse cellular functions, including the
G1–S phase transition of cell proliferation and the
formation of cell membranes 15. Statins may there-
fore inhibit cancer cell growth and lead to apoptotic
cell death through their inhibition of the mevalonate
pathway, although other mechanisms also have been
suggested.
Interleukin-18 (IL-18), a monocyte-derived cyto-
kine, is upstream of the production of interferon g from
T cells and natural killer cells 16,17. Interleukin-18 is
known to play an important role in regulating immune
responses, exhibiting significant antitumour activity 18.
The antitumour effects of IL-18 are mediated by acti-
vation of natural killer cells and cytotoxic T lympho-
cytes 19. In a previous study, we found that the statins
pravastatin, fluvastatin, and simvastatin induced pro-
duction of IL-18 by human monocytes 20,21. The ef-
fects of pravastatin, fluvastatin, and simvastatin were
abolished by the addition of mevalonate, indicating
the involvement of HMG-CoA reductase in the action of
the tested statins.
Angiogenesis is characterized by the formation
of new capillaries from existing vessels. It is well
known that tumour growth and metastasis both re-
quire growth of new blood vessels 22,23. The statins
lovastatin and cerivastatin are reported to inhibit tu-
mour-induced angiogenesis by reducing metabolites
of the mevalonate pathway that are pivotal in angio-
genesis 24,25.
The foregoing observations suggest that the an-
ticancer effect of statins depends on the apoptosis of
cancer cells, the production of IL-18 by monocytes,
and the inhibition of angiogenesis. However, the ef-
fects of statins on cancer are not completely under-
stood. Further experimental research will be useful
in clarifying this complex relationship.
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